Get started
Author

Michael Youdell

Roles for Ctk1 and Spt6 in Regulating the Different Methylation States of Histone H3 Lysine 36
2008 · Michael L. Youdell, Kelby O. Kizer, et al. · Molecular and Cellular Biology · 163
In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer
2020 · Sudhir B. Malla, David J. Fisher, et al. · Clinical Cancer Research · 28
PDF
A Machine Learning Model of Complete Response to Radiation in Rectal Cancer Reveals Immune Infiltrate and TGFβ Signalling as Key Predictors
2022 · Enric Domingo, Sanjay Rathee, et al. · EBioMedicine · 25
PDF
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
2025 · Gusztav Milotay, Martin Little, et al. · Nature Medicine · 23
Image-Based Consensus Molecular Subtyping Refines Prognostication in Stage II/III Colorectal Cancer: A Retrospective Analysis of the SCOT Trial
2026 · Maxime W. Lafarge, Andrea Harkin, et al. · Journal of Clinical Oncology
PDF
Cytomegalovirus infection protects against metastatic melanoma and modulates oncological outcome and toxicity to checkpoint immunotherapy
2024 · Gusztav Milotay, Martin Little, et al. · medRxiv
Supplementary Data from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer
2023 · Sudhir B. Malla, David J. Fisher, et al.
Supplementary Results from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer
2023 · Sudhir B. Malla, David J. Fisher, et al.
supplementary figures, from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer
2023 · Sudhir B. Malla, David J. Fisher, et al.
Data from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer
2023 · Sudhir B. Malla, David J. Fisher, et al.
Supplementary Data from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer
2023 · Sudhir B. Malla, David J. Fisher, et al.
Works count: 12
Citation count: 239
H-index: 4
I10-index: 4
Year
Topic
Type